Quantcast

Latest Ampio Pharmaceuticals Inc. Stories

2014-06-05 08:28:34

GREENWOOD VILLAGE, Colo., June 5, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the appointment of Gregory A. Gould as Chief Financial Officer, Treasurer, and Corporate Secretary. Mr. Gould, a veteran of the pharmaceutical and life sciences industry, is joining the company effective June 10(th), 2014. Mark McGregor, the company's current CFO, will retire from Ampio Pharmaceuticals following a transition period later this year....

2014-05-27 12:32:32

LONDON, May 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Diabetic Nephropathy Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/diseases/global_diabetic_nephropathy_market_2014_2018.html About Diabetic NephropathyDiabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the...

2014-05-21 08:29:02

GREENWOOD VILLAGE, Colo., May 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the Jefferies Global Healthcare Conference in New York City. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Dr. Vaughan Clift, MD, Ampio's Chief Regulatory and Medical Affairs Officer, and Josh Disbrow, Ampio's Chief Operating Officer and Chief Executive Officer of Ampio subsidiary Luoxis...

2014-04-22 08:33:07

Company Achieves Second Regulatory Clearance for Oxidation-Reduction Potential Platform GREENWOOD VILLAGE, Colo., April 22, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained Health Canada Class II Medical Device approval for its RedoxSYS(TM) Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body....

2014-04-21 08:25:38

GREENWOOD VILLAGE, Colo., April 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Vyrix. Vyrix has applied for a listing of its common...

2014-04-10 08:29:34

GREENWOOD VILLAGE, Colo., April 10, 2014 /PRNewswire/ -- Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's sexual health, has signed an agreement with Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute...

2014-04-09 08:29:01

GREENWOOD VILLAGE, Colo., April 9, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the results of the 20 weeks extension of the Ampion(TM) SPRING study will be presented by Dr. Nathan Wei, MD of the Arthritis Treatment Center Frederick, MD at the Western Orthopedic Association Conference in July 2014. http://www.woa-assn.org/. This 20-week extension of a multicenter, randomized, vehicle-controlled, double-blind study (NCT01839331) evaluated the safety...

2014-04-02 08:33:12

Regulatory Clearance Enables Commercialization in Europe and other Key Markets GREENWOOD VILLAGE, Colo., April 2, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS(TM) Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in strategic...

2014-03-11 08:29:56

GREENWOOD VILLAGE, Colo., March 11, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced dial in details for a scheduled investor call, Thursday, March 13, 4:00 PM EDT. Participants are invited to dial in using the instructions as follows: Number and Participant Passcode: Participant Passcode: 606197 Int'l Toll: 719-785-1745 US/CAN Toll free: 888-471-3830 Questions can be emailed in advance to April Ramirez at aramirez@ampiopharma.com Access will...

2014-03-05 12:27:16

GREENWOOD VILLAGE, Colo., March 5, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the closing of its sale of 9,775,000 shares of common stock in an underwritten public offering. The total number of shares of common stock sold reflects the full exercise by the underwriters of their option to purchase an additional 1,275,000 shares of common stock. As a result, Ampio Pharmaceuticals, Inc. has received gross proceeds of approximately $68 million. Net...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related